The missing voice of patients in drug-safety reporting.
作者信息
Basch Ethan
机构信息
Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, USA.
出版信息
N Engl J Med. 2010 Mar 11;362(10):865-9. doi: 10.1056/NEJMp0911494.
Abstract
摘要
相似文献
1
The missing voice of patients in drug-safety reporting.
N Engl J Med. 2010 Mar 11;362(10):865-9. doi: 10.1056/NEJMp0911494.
2
Regulatory experts debate FDA's authority.
Am J Health Syst Pharm. 2007 May 1;64(9):910, 912. doi: 10.2146/news070040.
3
The future of population-based postmarket drug risk assessment: a regulator's perspective.
Clin Pharmacol Ther. 2013 Sep;94(3):349-58. doi: 10.1038/clpt.2013.118. Epub 2013 Jun 5.
4
Impact of new regulations for pediatric labeling by the Food and Drug Administration.
Pediatr Nurs. 2000 Jan-Feb;26(1):95-6.
5
[Direct reporting by patients of adverse drug reactions in Spain].
Farm Hosp. 2013 Jan-Feb;37(1):65-71. doi: 10.7399/FH.2013.37.1.121.
6
Flight 483 now boarding.
Altern Med Rev. 2010 Sep;15(3):183-5.
7
Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Clin Ther. 2021 Feb;43(2):380-395. doi: 10.1016/j.clinthera.2020.12.011. Epub 2021 Jan 24.
8
Reporting Adverse Drug Events.
Am J Gastroenterol. 2019 Sep;114(9):1411-1413. doi: 10.14309/ajg.0000000000000374.
9
New FDA regulation to improve safety reporting in clinical trials.
N Engl J Med. 2011 Jul 7;365(1):3-5. doi: 10.1056/NEJMp1103464. Epub 2011 Jun 8.
10
Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
JAMA. 2018 Aug 14;320(6):547-548. doi: 10.1001/jama.2018.8408.
引用本文的文献
1
Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational Study.
Cancer Med. 2025 Sep;14(17):e71161. doi: 10.1002/cam4.71161.
2
Effectiveness of symptom monitoring on electronic patient-reported outcomes (ePROs) among patients with lung cancer: a systematic review and meta-analysis.
NPJ Digit Med. 2025 Jul 3;8(1):399. doi: 10.1038/s41746-025-01812-x.
3
A nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls.
Qual Life Res. 2025 Jul 2. doi: 10.1007/s11136-025-04017-7.
4
Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania.
Curr Oncol. 2025 Jun 5;32(6):332. doi: 10.3390/curroncol32060332.
5
ENABLE-App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc. 2025 May 26;14:e69855. doi: 10.2196/69855.
6
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
Future Oncol. 2025 May;21(12):1511-1523. doi: 10.1080/14796694.2025.2491297. Epub 2025 May 7.
7
Extraction of First Permanent Molars in Children-A Comprehensive Review of History, Aim, Space Closure and Other Consequences.
J Clin Med. 2025 Mar 25;14(7):2221. doi: 10.3390/jcm14072221.
8
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review.
JNCI Cancer Spectr. 2025 Apr 30;9(3). doi: 10.1093/jncics/pkaf036.
9
Putting Patients First: Pragmatic Trials in Gynecologic Oncology.
Curr Oncol. 2025 Feb 27;32(3):139. doi: 10.3390/curroncol32030139.
10
Exploring Usability of a Clinical Decision Support System for Cancer Care: A User-Centered Study.
Cancer Rep (Hoboken). 2025 Mar;8(3):e70173. doi: 10.1002/cnr2.70173.
本文引用的文献
1
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. doi: 10.1093/jnci/djp386. Epub 2009 Nov 17.
2
Agreement between patient-reported symptoms and their documentation in the medical record.
Am J Manag Care. 2008 Aug;14(8):530-9.
3
Patient-reported medication symptoms in primary care.
Arch Intern Med. 2005 Jan 24;165(2):234-40. doi: 10.1001/archinte.165.2.234.
4
Better reporting of harms in randomized trials: an extension of the CONSORT statement.
Ann Intern Med. 2004 Nov 16;141(10):781-8. doi: 10.7326/0003-4819-141-10-200411160-00009.
Zotero 插件